BIOCORP Signs Distribution Agreement for Mallya Technology With Roche Diabetes Care France
30.6.2020 08:30:00 EEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, announces today the signature of a distribution contract for its Mallya connected device with Roche Diabetes Care France.
As part of the agreement, Roche Diabetes Care France will distribute Mallya to pharmacies in France. This medical device is an intelligent 2-year reusable injector pen sensor that is compatible with the majority of insulin injection pens, both disposable and reusable. It automatically collects the insulin dose delivered with near 100% accuracy.
In the future, Mallya will also be part of the RocheDiabetes ecosystem consisting of connected blood glucose meters (Accu-Chek Mobile, Accu-Chek Guide) and digital solutions for better patients care.
Gluci-Chek is a smartphone application regularly used by nearly 60,000 diabetic patients in France. It brings together three major functionalities for personalized diabetes management: a carbohydrate calculation tool with visualization of portions on the plate, a self-monitoring glycemic logbook and a graphic visualization of glycemic results.
Thanks to Mallya, the patient will no longer have to manually report the insulin doses injected in the future since, once the sensor is paired with the Gluci-Chek application, the data will be automatically reported and displayed in the blood glucose monitoring logbook, regardless of the insulin pen1.
Frédéric Jacquey, President of Roche Diabetes Care France: “The signature of this agreement with Biocorp represents a fundamental step in the development of our ecosystem to improve the care of diabetic patients and their exchanges with healthcare professionals. With innovative technology like Mallya, we will soon be able to offer a unique offering for optimal patient care that integrates blood glucose data from our meters via Gluci-Chek and automatic insulin data via Mallya.”
Éric Dessertenne, CEO of BIOCORP: “Roche is the second pharmaceutical giant to integrate our Mallya connected device for optimal monitoring of diabetic patients into its commercial offer. I would like to thank the teams at Roche Diabetes Care France for their responsiveness over the last few weeks. This new structuring agreement confirms the ambitions presented to all our shareholders in early 2020 on the market of digitalization of diabetes and the considerable commercial potential of Mallya. With a partner of the calibre of Roche, we are confident that a large number of diabetics will quickly be able to benefit from the real benefits offered by Mallya on the secure monitoring of their daily insulin intake."
ABOUT DE ROCHE DIABETES CARE FRANCE
Roche Diabetes Care is a healthcare company specializing in diabetes. For more than 40 years, it has been designing solutions to meet the needs of both patients and healthcare professionals: medical devices (blood glucose meters, lancing devices, insulin pumps), services (information and therapeutic education support) and digital solutions (applications, platform for sharing blood glucose data between patients and healthcare professionals). By creating an ecosystem connecting medical devices and digital solutions, Roche Diabetes Care is paving the way for personalized diabetes management with the aim of facilitating and optimizing the management and monitoring of this complex disease.
Roche Diabetes Care France is a subsidiary of the Roche Group in France, alongside Roche SAS France and Roche Diagnostics France. For more information, please visit www.roche.fr.
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
Follow us on Twitter @BIOCORPSystems
1 SoloStar de Sanofi – KwikPen de Eli Lilly – FlexPen de Novo Nordisk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005362/en/
Contact information
BIOCORP CONTACTS
Sylvaine Dessard
rp@biocorp.fr
+ 33 (0)6 88 69 72 85
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26
ROCHE DIABETES CARE FRANCE CONTACTS
Myriam Hamza
rochediabpresse@havas.com
+33 (0)6 45 87 46 51
Raphaële Badel
Raphaele.badel@roche.com
+33 (0)7 77 34 60 59
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 20:10:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic cancer and colorectal cancer, our TGFβR2×PD-1 bispecific antibody in microsatellite stable colorectal cancer and our CDK2 inhibitor in recurrent epithelial ovarian cancer – investigational approaches that reflect our focus on areas where there is significant need for novel therapies." Details on key data presentations at ESMO include: Rapid Oral Presentations INCB161734 (KRAS G12D) Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Mono
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 15:24:00 EEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 13:30:00 EEST | Press release
The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025, approaching the size of the entire US e-commerce market, according to market data cited in the report. Yet 68% of consumers in North America and 67% in Europe have never once bought a product through social media, and roughly two-thirds
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 13:30:00 EEST | Press release
Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, development and commercialization. The collaboration now runs across continents, between Aqemia researchers in Paris and London and San
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS, Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 13:17:00 EEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom